A New Platform for Vaccine Delivery Capable of Eliciting a Mucosal Immune Response

Daniel Stein and Phillip DeShong of the University of Maryland in the U.S. will construct and test a vaccine platform that utilizes low-cost, stable surfactant vesicles to deliver antigens for a sustained mucosal immune response. If successful, the platform could be used to develop low-cost vaccines for bacterial infections where carbohydrates form the basis of protective immunity, such as bacterial pneumonia and diarrheal diseases.